Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Aug 5;97(3):857-65.
doi: 10.1016/j.bpj.2009.04.059.

Molecular and mesoscale mechanisms of osteogenesis imperfecta disease in collagen fibrils

Affiliations

Molecular and mesoscale mechanisms of osteogenesis imperfecta disease in collagen fibrils

Alfonso Gautieri et al. Biophys J. .

Abstract

Osteogenesis imperfecta (OI) is a genetic disorder in collagen characterized by mechanically weakened tendon, fragile bones, skeletal deformities, and in severe cases, prenatal death. Although many studies have attempted to associate specific mutation types with phenotypic severity, the molecular and mesoscale mechanisms by which a single point mutation influences the mechanical behavior of tissues at multiple length scales remain unknown. We show by a hierarchy of full atomistic and mesoscale simulation that OI mutations severely compromise the mechanical properties of collagenous tissues at multiple scales, from single molecules to collagen fibrils. Mutations that lead to the most severe OI phenotype correlate with the strongest effects, leading to weakened intermolecular adhesion, increased intermolecular spacing, reduced stiffness, as well as a reduced failure strength of collagen fibrils. We find that these molecular-level changes lead to an alteration of the stress distribution in mutated collagen fibrils, causing the formation of stress concentrations that induce material failure via intermolecular slip. We believe that our findings provide insight into the microscopic mechanisms of this disease and lead to explanations of characteristic OI tissue features such as reduced mechanical strength and a lower cross-link density. Our study explains how single point mutations can control the breakdown of tissue at much larger length scales, a question of great relevance for a broad class of genetic diseases.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Hierarchical collagen structure from tropocollagen molecule to fiber level, and location of OI point mutations in the tropocollagen molecule. (a) Hierarchical structure of collagen and associated length scales; including: single tropocollagen molecule, collagen fibrils (staggered arrays of tropocollagen molecules), and fibers/fascicles. (b) Molecular geometry of the tropocollagen molecule, indicating the residue that is replaced in the mutation (thick visualization). All tropocollagen-like peptides considered in this study share the same structure, consisting of three identical chains made of Gly-Pro-Hyp triplets: [(GPO)5-(XPO)-(GPO)4]3. The X position of each chain (highlighted in red in the upper part) is one of seven replacing residues related to OI (lower part).
Figure 2
Figure 2
Reduction of Young's modulus of a single tropocollagen molecule, as a function of the (a) glycine replacement and as a function of (b) OI severity. In a, the elastic properties of a tropocollagen molecule are depicted as a function of the replacing amino acid residues, which are ordered based on the resulting disease severity (from physiological glycine [GLY] reference case to the most severe OI mutation [ASP]). (b) Young's modulus normalized by the reference glycine case, as a function of the mutation severity. More severe mutations tend to lead to a greater reduction of the elastic modulus, with greatest reduction of 15%. Data replotted from Gautieri et al. (13) and shown here for completeness.
Figure 3
Figure 3
Change of intermolecular adhesion profile, adhesion energy ɛ and intermolecular spacing dmin as a function of OI severity. (a) Displays effective adhesion profiles for various mutations, including the reference case (the effective adhesion profile between pairs of molecules [top left] is obtained by averaging over all six directions in the hexagonal packing [top right]). As the mutations become more severe, the adhesion profiles display a more shallow profile with an equilibrium spacing shifted to larger values. (b) The intermolecular adhesion energy ɛ plotted over OI severity, reflecting the reduction of adhesion as the mutations become more severe. (c) The intermolecular equilibrium spacing plotted over OI severity, reflecting the increase of intermolecular distance as the mutations become more severe. In each panel, the reference case (=absence of mutations) is depicted with a square.
Figure 4
Figure 4
Effect of increased intermolecular distance reduces the probability of intermolecular cross-linking in collagen fibrils. (a) The geometry of cross-linking tropocollagen molecules. The core of the collagen molecule plus the lysine side chains can be considered as a sphere with radius r. For the cross-link reaction to occur, the end groups of the two lysine residues must approach one another in space and be at the right orientation with one another for the reaction to take place. This means that the bigger the overlap between two collagen spheres (that is, the closer the tropocollagen molecules are packed in the fibril), the greater is the probability of the cross-link forming (21). (b) The overlap volume (relative to the reference case, Gly) between two collagen spheres as a function of the distance between the spheres (dark line). The overlap volume is given by Eq. S3. We use a value of r = 1.14 nm, which is given by the sum of the radius of the collagen core (0.5 nm; see Fratzl and Weinkamer (26)) plus the length of the lysine side chain (0.64 nm; see Miles et al. (21)). The plot is then populated with the relative overlap volumes calculated in the presence of each specific OI mutation. In this case we use as intermolecular equilibrium distance dmin (see Table S2). The presence of OI mutations, by increasing the intermolecular distance between tropocollagen molecules, considerably reduces the volume of the overlap zone, and thus the probability of the cross-link formation. This mechanism could explain the lower level of cross-links observed in OI (28,29).
Figure 5
Figure 5
Influence of OI mutations on the mechanical properties of a collagen fibril, leading to a significant reduction of mechanical strength and yield strain (for most severe mutation, located at the end of the molecule). (a) The decrease of the strength for a mutation (in a cross-link deficient fibril and highly cross-linked fibril), including a qualitative comparison with experimental results (31) in OI tendon (note the difference in scale; our studies are focused on single collagen fibrils; the experiments have been carried out at much larger tendon tissue scales). (b) The stress-strain curve for the reference case and the mutated case, showing that the presence of mutations can severely influence the overall mechanical signature (highly cross-linked fibril). Intermolecular sliding sets in at 30% vs. 42% in the mutated fibril, and the maximum stress is significantly reduced (to ∼50% of its reference value). The small-deformation elastic modulus is reduced by ∼15% under the presence of the OI mutation. (c) The ratio of the maximum shear stress in the mutated versus the nonmutated system, based on the average shear stress along tropocollagen molecules, σshear,maxmut/σshear,maxref for both the cross-link deficient fibril and highly cross-linked fibril (the stress is evaluated at identical strain levels immediately before the onset of failure). The average maximum shear stress is 68% and 38% higher for the cross-link deficient fibril and highly cross-linked fibril, respectively, causing fibril failure via intermolecular slip.

Similar articles

Cited by

References

    1. Peltonen L., Palotie A., Prockop D.J. A defect in the structure of type I procollagen in a patient who had osteogenesis imperfecta: excess mannose in the COOH-terminal propeptide. Proc. Natl. Acad. Sci. USA. 1980;77:6179–6183. - PMC - PubMed
    1. Rauch F., Glorieux F.H. Osteogenesis imperfecta. Lancet. 2004;363:1377–1385. - PubMed
    1. Primorac D., Rowe D.W., Mottes M., Barisic I., Anticevic D. Osteogenesis imperfecta at the beginning of bone and joint decade. Croat. Med. J. 2001;42:393–415. - PubMed
    1. Sillence D.O., Senn A., Danks D.M. Genetic heterogeneity in osteogenesis imperfecta. J. Med. Genet. 1979;16:101–116. - PMC - PubMed
    1. Kozloff K.M., Carden A., Bergwitz C., Forlino A., Uveges T.E. Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength. J. Bone Miner. Res. 2004;19:614–622. - PubMed

Publication types

MeSH terms